$RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is RXRX up today? It is at $3.19 (+0.79%), and our scanner flagged it 184 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment RXRX spikes, and full due diligence on RXRX — key stats, earnings, dilution and insider activity. Free.
Get free $RXRX alerts the moment volume spikes
Our scanner flagged $RXRX 184 times in the last 30 days. Create a free account to track $RXRX, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $3.19
- Change today
- +0.79%
- Previous close
- $3.17
- 52-week range
- $2.77 – $7.18
- Market cap
- $534M
- Short interest
- 180.8M ▲ +5% vs prior · as of 2026-07-15
- Short % of float
- 33.8%
- Days to cover
- 6.7d
- Avg daily volume
- 24.9M
- Sector
- Health Care
- Industry
- Biological Products, (No Diagnostic Substances)
- Exchange
- XNAS
- 5m
- 0.1x
- 15m
- 0.9x
- 1h
- 0.6x
- 1D
- 0.1x
Get free RXRX + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $RXRX up today?
RXRX is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on RXRX today, peaking at 10.5x its normal volume. Fresh from the SEC: RECURSION PHARMACEUTICALS, INC. filed a Quarterly report (10-Q). A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystQuarterly report (10-Q), from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
11 buys, 12 sells last 3 months (42/63 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Borgeson Blake Director | Sold (automatic/other) | -40K 0.02% of company | sold 0.6% | 6.22M | $158K at $3.96 | Jul 7, 26 |
Li Dean Y Director | Acquired (grant/award) | +4K | added 0.3% | 1.47M | n/a | Jul 1, 26 |
Dar Zavain Director | Acquired (grant/award) | +5K | added 2.2% | 241K | n/a | Jul 1, 26 |
Bumpus Namandje Director | Sold (automatic/other) | -4K | sold 3.0% | 128K | $13K at $3.18 | Jun 18, 26 |
Li Dean Y Director | Acquired (grant/award) | +88K 0.05% of company | added 6.4% | 1.47M | n/a | Jun 17, 26 |
Bumpus Namandje Director | Acquired (grant/award) | +88K 0.05% of company | added 100% | 132K | n/a | Jun 17, 26 |
Dar Zavain Director | Acquired (grant/award) | +88K 0.05% of company | added 60% | 236K | n/a | Jun 17, 26 |
Sun Elaine D Director | Acquired (grant/award) | +88K 0.05% of company | added 100% | 136K | n/a | Jun 17, 26 |
Michor Franziska Director | Acquired (grant/award) | +88K 0.05% of company | added 70% | 215K | n/a | Jun 17, 26 |
Hershberg Robert Director | Acquired (grant/award) | +88K 0.05% of company | added 100% | 162K | n/a | Jun 17, 26 |
Borgeson Blake Director | Acquired (grant/award) | +88K 0.05% of company | added 1.4% | 6.26M | n/a | Jun 17, 26 |
Taylor Ben R Officer | Sold (automatic/other) | -5K | sold 0.5% | 1.10M | $17K at $3.15 | Jun 15, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $RXRX runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- At-the-market (ATM) program — sells new shares into the market gradually over time · About $300M in size · Priced at $3.53/share
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$RXRX Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$RXRX Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
Stocks similar to RXRX
Comparable names in biological products, (no diagnostic substances), closest in size first.
RXRX stock FAQ
Why is $RXRX up today?
RXRX is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on RXRX today, peaking at 10.5x its normal volume. Fresh from the SEC: RECURSION PHARMACEUTICALS, INC. filed a Quarterly report (10-Q). A material company disclosure like this is often the real catalyst behind a move of this size.
What is the RXRX stock price today?
RXRX last traded at $3.19, up 0.79% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live RXRX alerts?
The RXRX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged RXRX 184 times in the last 30 days.
What exchange is RXRX on?
RXRX (Recursion Pharmaceuticals, Inc. Class A Common Stock) trades on XNAS, with a market cap of about $534M in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Is RXRX good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge RXRX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.